Vitafos

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vitafos

Vitafos is a combination pharmaceutical preparation distinguished by its dual system of Vitamin B1 derivatives, intended for oral administration. Its core function is to ensure optimal Thiamine (Vitamin B1) delivery to the body's tissues, particularly the nervous system.

Property	Description
Active ingredients	Benfotiamine, Thiamine Hydrochloride
Form	Oral Solid (Tablet or Capsule)
Pharmacological class	Vitamins, Thiamine Precursors
Common use	Thiamine replacement, Nerve function support
Origin	Synthetic (Benfotiamine) and Natural Salt (Thiamine HCl)

Vitafos: Definition, Class, and Differentiation

Vitafos is classified as a Vitamin B1 derivative and a Thiamine precursor, typically presented as an oral solid dosage form. This preparation is distinct because it is a combination product that pairs the readily absorbed, lipid-soluble Benfotiamine with the standard, water-soluble Thiamine Hydrochloride. This dual approach is clinically recognized for achieving superior therapeutic levels of Vitamin B1 compared to conventional single-salt thiamine preparations. Thiamine itself is globally recognized as an essential micronutrient for the human diet.

The Dual-Action Components: Benfotiamine and Thiamine Hydrochloride

Benfotiamine, a synthetic, lipid-soluble S-acyl derivative of Thiamine, is the key component providing the formulation's unique identity. This specialized structure grants Benfotiamine significantly higher bioavailability compared to traditional Thiamine salts. This allows for enhanced tissue penetration, especially into nerve cells, overcoming the absorption limitations of conventional Thiamine forms. The precise chemical structure of Benfotiamine is formally recognized for its role as a lipid-soluble thiamine precursor.

General Purpose: Supporting Nerve Function and Metabolism

The general purpose of Vitafos is the reliable replenishment of Thiamine reserves, an essential nutrient vital for cellular energy metabolism. By ensuring the availability of the active coenzyme, Thiamine Diphosphate (ThDP), the preparation supports healthy nerve function and aids the body in maintaining metabolic stability, a general benefit associated with adequate B-vitamin intake.

Regulatory References

What side effects are possible with Vitafos?

Possible side effects and safety information for Vitafos

Vitafos is typically classified as a specialized nutritional product or a food for special medical purposes, not as a prescription or over-the-counter pharmaceutical drug. Due to this regulatory status, its safety information is not documented using the formal, standardized frameworks—such as frequency-classified adverse reactions or System-Organ Class groupings—that authoritative government drug agencies (like the EMA or FDA) apply to medicines.

Adverse Reaction Documentation Scope

Since this product is not regulated as a drug, its regulatory safety profile does not include the following formal classifications:

Key adverse reaction categories: Not formally classified (e.g., by frequency or seriousness) in government drug regulatory safety documents.
Frequency classification: Not determined or reported using standardized categories (e.g., Common, Rare, Not Known).
Serious adverse reactions: No formal documentation of serious adverse reactions is maintained by major drug regulatory bodies.
Population-specific safety: No formal safety advisories specific to populations (e.g., pregnancy) are documented in pharmaceutical regulatory records.

Safety Classifications and Limitations

Regulatory frequency framework used: None used; the product is not subject to the mandatory reporting and safety documentation framework required for pharmaceutical drugs.
Regulatory basis: The product is not listed with a formal drug safety profile under major global pharmaceutical regulatory authorities (EMA, FDA, etc.).

Resulting Safety Structure

The safety information for this product is structured based on its status as a nutritional item rather than a drug. This categorization means that the official safety profile lacks the mandatory pharmaceutical drug reporting elements, such as formal classifications of adverse reactions by frequency or by affected body system. Consequently, governmental regulatory agencies do not provide official statements on comparative risk or incidence rates for adverse effects related to this product.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Vitafos, a combination of Thiamine derivatives, indicates a low risk of systemic toxicity from oral overconsumption. As a water-soluble vitamin, excess Thiamine is primarily managed by rapid renal excretion.

Documented Overdose Manifestations

Manifestations associated with high exposure are generally limited to hypersensitivity reactions. These signs may include flushing, itching (pruritus), hives (urticaria), sweating, nausea, and restlessness. The most severe outcomes, such as anaphylaxis and collapse, have been reported almost exclusively following high-dose parenteral (injection) administration of Thiamine, not typically oral intake.

Required Emergency Actions

Individuals must seek immediate medical attention or call emergency services if a severe allergic reaction is suspected. Urgent help is required for manifestations such as swelling of the face or throat (angioedema), severe difficulty breathing, or hypotension. Treatment for overdose is supportive and symptomatic; regulatory information confirms that no specific antidote is known for Thiamine overdosage. The national Poison Control Center should be contacted if an overdose is suspected.

Therapeutic Uses of Vitafos

Vitafos, a combination of Thiamine derivatives (Benfotiamine and Thiamine HCl), is used to provide targeted therapeutic support in clinical situations defined by Thiamine deficiency and its related symptomatic manifestations across the nervous and cardiovascular systems. Thiamine is recognized for its role in managing conditions like Beriberi and Wernicke-Korsakoff syndrome, which involve significant neurological and systemic disruption.

“This combination of B1 derivatives assists with maintaining functional stability and contributes to easing the overall symptom load during difficult episodes.”

Supportive Therapeutic Domains

This medication is commonly used to help manage the functional and sensory disruptions of peripheral nerve symptoms associated with chronic metabolic conditions (like diabetes), or systemic deficiency resulting from chronic alcohol use. The supportive relief contributes to improved day-to-day comfort and helps patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Neuropathic Discomfort

Vitafos is generally used in clinical settings that involve acute or unstable symptom patterns, offering supportive symptomatic relief when discomfort arises from symptom-driven clinical presentations, rather than from mechanical injury or inflammation.

Regulatory References

NIH MedlinePlus overview of Thiamine

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Vitafos

The eligibility and non-eligibility for Vitafos, a combination of Thiamine derivatives, are defined by strict regulatory criteria outlined in official government documentation.

Populations and Conditions for Restricted or Prohibited Use

Classification	Population or Condition
Contraindicated	Known Hypersensitivity to Thiamine Hydrochloride (Vitamin B1) or to any excipients.
Contraindicated	Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
Not Recommended	Children under three years of age, establishing a formal pediatric minimum.
Not Intended for Use	Pregnant women and Lactating (Breastfeeding) women.

Populations Allowed Under Standard Labeled Conditions

Use of Vitafos is permitted for adults and the elderly. The medicine is also permitted for use in children over three years of age. The regulatory structure is based on absolute prohibitions (contraindications) linked to specific ingredient sensitivities and excipient-related metabolic disorders, while defining clear age thresholds for allowed use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Vitafos, a combination of Thiamine derivatives, is defined by substances that can formally reduce the body's Thiamine levels, requiring specific regulatory caution. Official government drug documents primarily identify clinically significant exposure-modifying interactions rather than contraindicated combinations.

Documented Exposure-Altering Interactions

Several medicinal products are officially documented to affect the status or availability of Thiamine. Loop diuretics, such as Furosemide, are noted to increase the renal excretion of Thiamine, which decreases overall systemic exposure. The antineoplastic agent Fluorouracil is documented to interfere with Thiamine's metabolic processes, resulting in a reduction of the active vitamin's availability.

Transporter-mediated interactions are also recognized. Specifically, the Janus kinase inhibitor Fedratinib is formally stated to interact by inhibiting the Thiamine transporter SLC19A3. This interaction mechanism can lead to a state of Thiamine depletion.

Administration Constraints

Certain co-administered medicines require a mandatory separation of administration time. The potassium binder Patiromer is documented to decrease Thiamine levels via gastrointestinal binding and requires a regulatory-specified separation of at least three hours between doses. Regarding substances, chronic alcohol consumption is officially noted to predispose individuals to Thiamine deficiency, which heightens the clinical relevance of any interacting substance that further depletes Thiamine levels.

Mechanism of Action

How Vitafos Works

Vitafos is a nutritional supplement whose mechanism of action involves the physiological roles of its macronutrients and micronutrients in regulating foundational biological processes through nutrient supply.

Energy Substrate Mobilization

Vitafos provides a balanced caloric density via carbohydrates and fats, including Medium-Chain Triglycerides (MCTs), facilitating rapid absorption into systemic circulation via the portal vein. This domain enables the rapid provision of metabolic substrates necessary for mitochondrial function and cellular energy production across major organ systems.

Core Biomolecular Synthesis Support

The formulation supplies high biological value whey proteins, along with essential vitamins and minerals. These components act within the domains involving anabolism and biosynthesis, providing necessary amino acids and cofactors to modulate pathways essential for muscle protein synthesis, hematopoiesis, and bone matrix formation.

Intestinal and Immunological Pathway Engagement

A symbiotic blend of prebiotics and probiotics initiates signaling sequences that influence the composition and metabolic activity of the enteric microbiome. This modulates key pathways associated with intestinal barrier integrity and the development of mucosal immune responses.

Dosage and Administration Information

The usage protocol for the Vitafos combination—which contains Benfotiamine and Thiamine derivatives—provides a high-level guide to administration, dose ranges, and patient populations. This preparation is intended solely for Oral administration in the form of a Capsule, defining the route of intake.

Administration Scope

Entity	Administration Principle
Route of Administration	The preparation is restricted to Oral intake only.
Dosing Schedule	Established regimens for adults include three distinct patterns: 1 capsule once daily, 2 capsules once daily, or 1 capsule three times daily.
Timing in Relation to Meals	Specific instructions are not provided regarding administration timing with respect to food intake.
Age-Group Administration	Labeled dose patterns are defined exclusively for Adults. The product information does not specify use or dose adjustments for pediatric patients.

Procedural Structure and Context

The administration of the capsule form is not associated with any required dilution, reconstitution, or special preparation steps. The absence of specific instructions in the product information concerning missed doses or special procedural conditions indicates that adherence to the prescribed daily frequency is the primary requirement for its intended use. This standardized approach ensures that the use of the medicine, which may involve once-daily or three-times-daily dosing, aligns with the established parameters for the product. The label confines the indicated administration to adults, limiting the scope of its general usage patterns.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vitafos

Evidence for Use in Symptomatic Peripheral Neuropathy

Research has explored the use of the active components contained in Vitafos, particularly Benfotiamine, in settings where nerve symptoms arise from systemic problems, such as Diabetic Polyneuropathy (DPN) and nerve issues related to chronic alcohol use. The research in this area includes multiple Randomized Controlled Trials (RCTs), which are considered the highest standard of evidence, alongside systematic reviews that pool the findings of these trials.

Studies examined a variety of outcomes related to physical discomfort, including patient-reported experiences of specific symptoms like pain, burning, numbness, and tingling (paresthesia). The findings describe patterns observed in these short-term studies, where some trials reported measurements that described patterns of change in certain nerve symptoms, especially pain, when compared to a placebo. However, the evidence relating to overall changes in all nerve symptoms was mixed, meaning findings were mixed across different studies. The objective functional measurements were also not consistently demonstrated in all of the observed populations. Research contributes to the broader evidence landscape by describing short-term symptomatic changes, but it is not yet clear whether longer-term structural or functional recovery is established.

Evidence for Use in Cognitive Support

Research has explored the active components to examine their relevance in settings of cognitive function. The research in this area is generally limited to Phase 2 Randomized Controlled Trials, which are initial-stage studies designed to explore concepts before large-scale testing. These trials evaluated older adults with Mild Cognitive Impairment (MCI) or Mild Dementia associated with early Alzheimer's disease.

Studies monitored changes in cognitive function scales and brain imaging biomarkers. The data for this application are still emerging, as these are primarily pilot studies. The findings describe patterns observed that sometimes described a difference in the rate of cognitive score change over the study period compared to the control group. However, the reported changes often did not reach the threshold for statistical certainty required for a definitive conclusion about clinical effect. Research highlights what is known, but certainty remains low for this potential application.

Key Studies & References Thiamine - MedlinePlus Drug Information (General Thiamine Information)

Frequently Asked Questions (FAQ)

Common questions about Vitafos (FAQ)

Q: What are the common signs of a Vitafos overdose?

Regulatory information indicates that instances of excessive intake of thiamine derivatives are uncommon, but certain effects have been reported. These generally concern the cardiovascular system, such as an increase in heart rate, or certain neurological changes. If signs of potential over-exposure are observed, contact emergency medical services or a healthcare professional immediately.

Q: How long does it take for Vitafos to start working for nerve symptoms?

Official studies exploring thiamine derivatives, which are components of Vitafos, suggest that patient responses may vary. Research studies have described patterns where some participants reported changes in symptoms, such as pain or tingling, during trial periods, sometimes within four to twelve weeks of use. However, individual experiences depend heavily on the specific underlying condition and metabolic factors.

How should Vitafos be stored and disposed of?

The storage and disposal of Vitafos, an oral Thiamine derivative, must follow specific regulatory conditions to maintain product stability and ensure household safety.

Storage Requirements

Official labeling for Thiamine products mandates storage at controlled room temperature, generally defined as between 15 C and 30 C (59 F and 86 F). The product must be stored in its original closed container to ensure protection from degradation. It is strictly required to store the medicine away from heat, moisture, and direct light. The container should be kept tightly closed, and the product must be kept from freezing.

Disposal and Safety

As a crucial child-protection measure, the medicine must be stored out of the reach and sight of children. To prevent accidental ingestion, patients are officially instructed to not keep outdated medicine or medicine no longer needed. Disposal of unused or expired product should follow general disposal guidelines for household medicine, such as utilizing local drug take-back programs or mixing the product with an undesirable substance before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Colombia

Taiwan

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z